GlassScriptPhysician profile
Alistair W Co
NPI 1194971028
$8,094.11
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,525 · 2020: $1,740 · 2021: $2,141 · 2022: $1,544 · 2023: $1,064 · 2024: $80.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,144.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,041.79 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,020.76 | 2019-2023 | Breztri |
| Abbvie INC. | $905.13 | 2019-2023 | Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $851.25 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $641.50 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $524.93 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $466.65 | 2019-2022 | |
| Pfizer INC. | $428.08 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $338.02 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $250.42 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $213.50 | 2022-2024 | |
| Amgen INC. | $209.99 | 2019-2023 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $197.34 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $128.67 | 2022 | |
| Merck Sharp & Dohme LLC | $106.78 | 2019-2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alistair Co listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.